ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2514

Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
Abstract Number: 2515

The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
Abstract Number: 2516

Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
Abstract Number: 2517

Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
Abstract Number: 2518

Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
Abstract Number: 2519

A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Abstract Number: 2520

Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Abstract Number: 2521

DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
Abstract Number: 2522

Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
Abstract Number: 2523

Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
Abstract Number: 2524

Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort
Abstract Number: 2525

Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Abstract Number: 2526

Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review
Abstract Number: 2527

Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Abstract Number: 2528

Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].